(Q54752770)

3 June 2018

title

Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas. (English)

1 reference

3 June 2018

0 references

2

1 reference

3 June 2018

Gabor Halmos

6

object named as

Gabor Halmos

1 reference

3 June 2018

Karoly Szepeshazi

1

object named as

Karoly Szepeshazi

1 reference

3 June 2018

author name string

Attila Nagy

3

1 reference

3 June 2018

Brady W Wagner

4

1 reference

3 June 2018

Ana Maria Bajo

5

1 reference

3 June 2018

language of work or name

English

0 references

publication date

1 October 2003

1 reference

3 June 2018

number of pages

10

1 reference

inferred from page(s)

published in

Cancer

1 reference

3 June 2018

volume

98

1 reference

3 June 2018

issue

7

1 reference

3 June 2018

page(s)

1401-1410

1 reference

3 June 2018

cites work

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Estimates of the worldwide mortality from 25 cancers in 1990.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Adjuvant therapy for noncolorectal cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Hypothalamic hormones and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Coexpression of the gastrin and somatostatin genes in differentiating and neoplastic human cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Somatostatin binding in normal and malignant human gastrointestinal mucosa

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Distribution of somatostatin receptor messenger RNAs in the rat gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

A human gastric cancer cell line possesses a functional receptor for gastrin-releasing peptide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Signaling mechanisms regulating bombesin-mediated AP-1 gene induction in the human gastric cancer SIIA

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Characterization of gastrin-releasing peptide receptors aberrantly expressed by non-antral gastric adenocarcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Molecular pharmacology of somatostatin receptor subtypes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Characterization of a bombesin/gastrin-releasing peptide receptor on a human gastric-cancer cell line

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Messenger RNA expression of somatostatin receptor subtypes in human and rat gastric mucosae

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Mechanisms of antineoplastic action of somatostatin analogs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Somatostatin analogs and radiopeptides in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Cloning of a receptor for amphibian [Phe13]bombesin distinct from the receptor for gastrin-releasing peptide: identification of a fourth bombesin receptor subtype (BB4)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11649

7 January 2021

Identifiers

DOI

10.1002/CNCR.11649

1 reference

3 June 2018

release_mgxaomvx7fg43a7xvjfxfnfvxq

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mgxaomvx7fg43a7xvjfxfnfvxq

24 November 2022

mapped directly with Wikidata item

1 reference

3 June 2018